US FDA panel backs approval for Eisai-Biogen Alzheimer's drug Leqembi

Expected FDA approval would make Leqembi the first in its class of drugs that work by removing sticky amyloid plaques from the brain to achieve the regulatory milestone.

Related Keywords

Bengaluru ,Karnataka ,India ,United States ,Chicago ,Illinois ,Americans ,Tanya Simuni ,Joanne Pike ,Khushi Mandowara ,Robert Alexander ,Leroy Leo ,Julie Steenhuysen ,Banner Alzheimer Institute ,Drug Administration ,Northwestern University Feinberg School Of Medicine ,Thomson Reuters Trust Principles ,Alzheimer Association ,Advisory Committee ,Reuters ,Northwestern University Feinberg School ,Banner Alzheimer ,Thomson Reuters Trust ,Rsbi Regulatory Oversight ,Rhpi Approvals ,Rhpi Biopharma ,Rhpi Drug Device Trials ,Rhpi Regulatory ,Mtpix ,Bact ,Bioph ,Biz ,Cmpny ,Cprod ,Dement ,Drudev ,Fin ,Fins ,Fins08 ,Gen ,Genhlt ,Govact ,Govadm ,Hea ,Heca ,Humdis ,Insr ,Medreg ,Mrch ,Neurol ,Phag08 ,Phar ,Phar08 ,Phar1 ,Phmr ,Publ ,Regs ,Sci ,Easia ,Gamers ,Us ,Namer ,Asxpac ,Asia ,Jp ,Ef Business Future Of Health ,Topnws ,Topcmb ,News1 ,